TISIDB

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Single-pass membrane protein Note=Localizes to the cortical endoplasmic reticulum at the endoplasmic reticulum-plasma membrane contact sites.
Domain	PF01237 Oxysterol-binding protein PF00169 PH domain
Function	Lipid transporter involved in lipid countertransport between the endoplasmic reticulum and the plasma membrane: specifically exchanges phosphatidylserine with phosphatidylinositol 4-phosphate (PI4P), delivering phosphatidylserine to the plasma membrane in exchange for PI4P, which is degraded by the SAC1/SACM1L phosphatase in the endoplasmic reticulum. Binds phosphatidylserine and PI4P in a mutually exclusive manner (PubMed:23934110, PubMed:26206935). May cooperate with NPC1 to mediate the exit of cholesterol from endosomes/lysosomes (PubMed:21220512). Binds 25-hydroxycholesterol and cholesterol (PubMed:17428193).

> Gene Ontology [ TOP ]
Biological Process	GO:0006066 alcohol metabolic process GO:0006869 lipid transport GO:0006892 post-Golgi vesicle-mediated transport GO:0006893 Golgi to plasma membrane transport GO:0008202 steroid metabolic process GO:0008203 cholesterol metabolic process GO:0010876 lipid localization GO:0015748 organophosphate ester transport GO:0015850 organic hydroxy compound transport GO:0015914 phospholipid transport GO:0015918 sterol transport GO:0016125 sterol metabolic process GO:0030301 cholesterol transport GO:0048193 Golgi vesicle transport GO:0098876 vesicle-mediated transport to the plasma membrane GO:1901615 organic hydroxy compound metabolic process GO:1902652 secondary alcohol metabolic process
Molecular Function	GO:0001786 phosphatidylserine binding GO:0005319 lipid transporter activity GO:0005496 steroid binding GO:0005543 phospholipid binding GO:0005548 phospholipid transporter activity GO:0008142 oxysterol binding GO:0015485 cholesterol binding GO:0032934 sterol binding GO:0035091 phosphatidylinositol binding GO:0043178 alcohol binding GO:0070273 phosphatidylinositol-4-phosphate binding GO:0072341 modified amino acid binding GO:1901981 phosphatidylinositol phosphate binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1482801: Acyl chain remodelling of PS R-HSA-1483206: Glycerophospholipid biosynthesis R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1483257: Phospholipid metabolism

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between OSBPL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of OSBPL5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of OSBPL5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.833	0.0325
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.107	0.46
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.628	0.553
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.078	0.845
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.099	0.964
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.301	0.912
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.186	0.614
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.166	0.875
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.144	0.908
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.749	0.526
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.839	0.238
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.166	0.102

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of OSBPL5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	28.6	-28.6	0.491
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OSBPL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OSBPL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OSBPL5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OSBPL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of OSBPL5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between OSBPL5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	OSBPL5
Name	oxysterol binding protein-like 5
Aliases	KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location	11p15.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting OSBPL5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse OSBPL5